ClinicalTrials.gg
Active, not recruitingNCT06884540OPUSUpdated Jul 1, 2026

Optimizing Patient-centred Outcomes Using Opioid Minimization Strategies: The OPUS Anesthesia Pilot Trial

An interventional study of Dexmedetomidine and lidocaine in Anesthesia, Anesthesia Complication and Surgery, sponsored by CHU de Quebec-Universite Laval. Active, not recruiting at 5 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by CHU de Quebec-Universite Laval · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 136 studies testing dexmedetomidine in Pain, Postoperative — 35 open to participants now, 38 under way, 5 of them phase 3. Dexmedetomidine · Pain, Postoperative.

Planned enrollment
37th of 136
100 · median 85
Started
2025
with 15 others
No phase
47 of 136
13 open now
Primary completion
2027-04
later than 21 of 37 live
Registered
104th of 136
by date

Among the 136 studies testing dexmedetomidine in Pain, Postoperative, this one is the 37th largest by planned enrollment, is one of 16 that started in 2025, is one of 47 with no phase, reaches primary completion later than 21 of the 37 other live ones, and was the 104th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

35 of the 136 studies testing dexmedetomidine in Pain, Postoperative are open now, in 9 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies testing dexmedetomidine in Pain, Postoperative, or all of them as a file.
02

Study summary

Up to 40% of patients experience suboptimal recovery in the days following major surgery, limiting their return to functional independence. Few preventive interventions exist, but intravenous dexmedetomidine and lidocaine administered during general anesthesia represent simple strategies that may significantly impact recovery and other patient-centred outcomes after surgery. The goal of this pilot trial is to determine the feasibility of conducting a phase 3 pragmatic adaptive multicentre trial to evaluate the impact of dexmedetomidine and lidocaine administered during major non-cardiac surgery on patient-centred outcomes.

03

Conditions studied

  • Anesthesia
  • Anesthesia Complication
  • Surgery
  • Quality of Life
  • Pain, Postoperative
  • Anesthesia Morbidity
  • Feasibility Studies
  • Patient-centredness

Browse trials for

Keywords

  • Pilot trial
  • Anesthesia
  • Quality of recovery
  • Postoperative pain
  • Opioid minimization strategies
  • Dexmedetomidine
  • Lidocaine
  • Patient-centred outcomes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults >/= 18 years.
  2. Having elective major non-cardiac surgery (i.e., planned duration >/= 1.5 hours and anticipated >/= 1 night hospital stay).
  3. Requiring general anesthesia.
  4. Able to complete baseline quality of recovery assessment.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with known to dexmedetomidine or lidocaine (e.g., allergy to alpha-2 agonists or local anesthetics, severe renal or hepatic failure, bradycardia or hypotension), as per routine assessment.
  2. Regular use of alpha-2 agonists or local anesthetics prior to hospitalization.
  3. Pregnant women.
  4. Planned use of regional analgesia (i.e., epidural, peripheral nerve block, trunk nerve block) in conjunction with general anesthesia. Local anesthetics such as lidocaine are administered as part of regional analgesia technique. Combination with intravenous lidocaine is contraindicated to avoid exceeding therapeutic concentration.
  5. Neurosurgical procedures except for spine surgery.
  6. Planned postoperative intubation after PACU discharge.
  7. No fixed address.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Intraoperative intravenous dexmedetomidine

    Drug: Dexmedetomidine

  • Experimental
    Intraoperative intravenous lidocaine

    Drug: lidocaine

  • Other
    Usual care

    Other: control group

Interventions

  • Intravenous bolus: between 0.2 and 0.5 mcg/kg. followed by Intravenous infusion: ranging from 0.2 to 0.7 mcg/kg/h to the discretion of the attending anesthesiologist. Bolus will be initiated prior to surgical incision and infusion will be stopped at wound closure.

  • Intravenous bolus: between 0.5 and 1.5 mg/kg. followed by Intravenous infusion: ranging from 0.5 to 2.0 mg/kg/h to the discretion of the attending anesthesiologist. Bolus will be initiated prior to surgical incision and infusion will be stopped at wound closure.

  • Othercontrol group

    Usual care where systemic dexmedetomidine is not allowed and systemic lidocaine is permitted only for the prevention or treatment of propofol injection pain.

06

What researchers measure

Primary outcomes

  1. Recruitment rate

    Number of patients who are approached to participate by the study team and who consent to participate in the study.

    Time frame: 1 week

Secondary outcomes

  1. Proportion of participants receiving dexmedetomidine

    Proportion of patients in the dexmedetomidine group who receive per protocol treatment (i.e. they receive dexmedetomidine during general anesthesia).

    Time frame: 24 hours

  2. Proportion of participants receiving lidocaine

    Proportion of patients in the lidocaine group who receive per protocol treatment (i.e. they receive lidocaine during general anesthesia).

    Time frame: 24 hours

  3. Completeness of data collection for outcome measures

    Completeness of data collection, defined as the percentage of instruments or data fields completed with at least 90% of expected forms or relevant fields completed at each time point for each instrument and participant.

    Time frame: 6 months

  4. Sex representativeness of participants

    Proportion of female participants enrolled in the trial.

    Time frame: 6 months

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Apr 2027, 21 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 21 months is above that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2025
First posted
Mar 19, 2025
StartActual
Jul 15, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Oct 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06884540
Collaborators
Canadian Perioperative Anesthesia Clinical Trials (PACT) Group, Canadian Institutes of Health Research (CIHR), International Anesthesia Research Society (IARS)
Responsible party
Sponsor
First posted
Mar 19, 2025
Start date
Jul 15, 2025
Primary completion
Apr 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Jul 1, 2026

Study contacts

Michael Verret, MD PhD FRCPC
principal investigator · CHU de Quebec-Université Laval Research Center
Dean A. Fergusson, PhD
principal investigator · Ottawa Hospital Research Institute
Manoj M. Lalu, MD PhD FRCPC
principal investigator · Ottawa Hospital Research Institute
Alexis Turgeon, MD MSc FRCPC
principal investigator · CHU de Quebec-Université Laval Research Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexmedetomidine · Lidocaine

Start the discussion